Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KHK | P50053 | 3/20 | 0.49 |
| ▸ | GPR119 | Q8TDV5 | 3/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 4/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.38 |
| ▸ | THRB | P10828 | 2/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | HPGDS | O60760 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 3/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2551520 | 0.86 | KHK (0.46) | KHKGPR119HSD17B10KDM4EHPGD | |
| SCHEMBL2551697 | 0.84 | KHK (0.49) | KHKGPR119HSD17B10KDM4EHPGD | |
| SCHEMBL2553474 | 0.84 | KHK (0.71) | KHKGPR119HPGDALDH1A1HPGDS | |
| SCHEMBL2545137 | 0.81 | GPR119 (0.47) | KHKGPR119HSD17B10KDM4EHPGD | |
| SCHEMBL2549483 | 0.72 | KHK (0.68) | KHKGPR119HPGDPOLBUSP30 | |
| SCHEMBL12240045 | 0.72 | KHK (0.66) | KHKKDM4EHPGDALDH1A1 | |
| Hydrochloric Acid SCHEMBL2552475 | 0.71 | KHK (0.65) | KHKKDM4EHPGDALDH1A1 | |
| SCHEMBL2550885 | 0.70 | KHK (0.72) | KHKGPR119HSD17B10KDM4EHPGD | |
| Hydrochloric Acid SCHEMBL2549305 | 0.70 | KHK (0.66) | KHKHSD17B10KDM4EHPGDALDH1A1 | |
| SCHEMBL2580181 | 0.70 | KHK (0.61) | KHKHSD17B10KDM4EHPGDMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9771375-B2 | Indazole compounds useful as ketohexokinase inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2017-09-26 | — | — | US | disclosed |
| EP-2560962-B1 | INDAZOLE COMPOUNDS USEFUL AS KETOHEXOKINASE INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2015-05-20 | — | — | EP | disclosed |
| US-20140336170-A1 | INDAZOLE COMPOUNDS USEFUL AS KETOHEXOKINASE INHIBITORS | JANSSEN PHARMACEUTICA NV (US) | 2014-11-13 | — | — | US | disclosed |
| US-8822447-B2 | Indazole compounds useful as ketohexokinase inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2014-09-02 | — | — | US | disclosed |
| US-20110263559-A1 | INDAZOLE COMPOUNDS USEFUL AS KETOHEXOKINASE INHIBITORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2011-10-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140336170-A1 | INDAZOLE COMPOUNDS USEFUL AS KETOHEXOKINASE INHIBITORS | KHK, GCK, GCKR | KHK 1/4885GPR119 12/4885HSD17B10 279/4885 |
| US-20110263559-A1 | INDAZOLE COMPOUNDS USEFUL AS KETOHEXOKINASE INHIBITORS | KHK, GCK, GCKR | KHK 1/4885GPR119 12/4885HSD17B10 279/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.